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The mTOR inhibitor rapamycin significantly improves facial
angiofibroma lesions in a patient with tuberous sclerosis
Abstract
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with an incidence of
approximately one in 6000. It arises from a genetic abnormality involving either the TSC1 gene on
chromosome 9 or the TSC2 gene on chromosome 16. The protein product of TSC1 is hamartin and that
of TSC2 is tuberin. In cells, hamartin and tuberin form a complex which inhibits the mammalian target
of rapamycin (mTOR), a central controller of cell growth and proliferation. Angiofibroma affects
70-80% of patients with TSC, typically on the face. We report a patient with TSC with recurrent
life-threatening haemorrhage from both kidneys due to extensive angiomyolipoma formation leading to
bilateral nephrectomy and renal transplantation. Immunosuppressive treatment with rapamycin, a
specific mTOR inhibitor, initiated because of renal transplantation, reduced facial angiofibroma
dramatically.
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Case report 
Introduction 
One in six thousand persons is affected with the autosomal dominant disorder 
tuberous sclerosis complex (TSC, Bourneville-Pringle disease) 1. The underlying 
genetic abnormality involves either the TSC1 gene on chromosome 9 2, or the TSC2 
gene on chromosome 16 3. TSC1 and TSC2 genes encode the proteins hamartin and 
tuberin. Hamartin and tuberin form a complex, thereby inhibiting the mammalian 
target of rapamycin (mTOR), a central check-point of cell growth and proliferation 4-6. 
 
Tuberous sclerosis patients present with typical skin changes such as ash-leaf-like 
hypopigmented macules, Shagreen patch, molluscum pendulum, forehead fibrous 
plaque, confetti-like macules, Koenen tumors and facial angiofibromas 7. Facial 
angiofibroma manifests in youth and early adulthood and affects 70-80% of patients 
with tuberous sclerosis. Facial angiofibroma is often a major cosmetic problem of 
great concern to TSC patients. Typically, facial angiofibroma does not improve 
spontaneously and is frequently treated for the disfigurement. Common treatment 
modalities are dermabrasion, cryosurgery, curettage, chemical peeling, excision and 
laser therapy 7, which may only yield partial improvement and carry the risk of keloid 
formation. Here we report on a patient with tuberous sclerosis who underwent renal 
transplantation 8. Initial immunosuppressive treatment with tacrolimus was later 
switched to rapamycin, a specific mTOR inhibitor with anti-angiogenic potential. 
Subsequently, we observed great improvement of facial angiofibroma following 
rapamycin introduction, suggesting a pivotal role for mTOR in the formation of 
angiofibroma.  
Case description 
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A healthy 15 year-old girl presented with abdominal pain. On clinical examination 
small nodules on the convex facial surface were noted. Urinalysis revealed 
microhematuria without proteinuria. Kidney function was normal. Imaging studies 
showed enlargement of both kidneys with diffuse hypodense areas of high fat 
content, corresponding to multiple angiomyolipomas and isolated hematomas. 
Cortical tubers and subependymal nodules were detected in the brain. Skin changes 
included ash-leaf like hypopigmented macules and red grouped papules on convex 
skin surfaces of the face (Figure 1). The clinical presentations of the facial skin 
changes were consistent with facial angiofibroma. The mother also showed facial 
angiofibroma and Koenen tumors on the lateral nail plates. Her brother was 
diagnosed with diffuse bilateral angiomyolipomas in the kidneys. A clinical diagnosis 
of tuberous sclerosis complex (TSC) was made. A genetic examination of the patient 
and her mother revealed a novel nonsense mutation (c. 408C>A, Y130X) in the 
TSC2 gene, confirming the clinical diagnosis.  
 
Pronounced renal angiomyolipomata repeatedly led to intraabdominal hemorrhage. 
The amount of hemorrhage reached life-threatening levels. Eventually, both kidneys 
were removed and a living-donor kidney transplantation was performed at the age of 
21 years. Graft rejection was suppressed with tacrolimus 7 mg bid, mycophenolate 
mofetil 500 mg bid and prednisone 7.5 mg qd. Three months following 
transplantation, the immunosuppressive regimen was switched to rapamycin 3.5 mg 
qd, mycophenolate mofetil 500 mg bid and prednisone 7.5 mg qd in July 2006. 
 
The face of the patient was severely affected by the facial angiofibromas. During 
rapamycin treatment facial angiofibroma improved dramatically (Figure 1). Ash-leaf 
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like hypopigmented macules showed no change. The patient currently is well with 
stable renal transplant function without rapamycin-related side-effects. 
 
Discussion 
In patients with TSC, the loss or dysfunction of tuberin or hamartin causes 
constitutive activation of the mTOR pathway. The mTOR kinase is a key intermediary 
kinase in multiple mitogenic signalling pathways and plays a central role in 
modulating cellular proliferation, growth and angiogenesis. Patients with TSC display 
abnormal growth and blood vessels in different organs including the skin. Here we 
show as proof-of-concept in man that the specific mTOR inhibitor rapamycin reduces 
facial angiofibroma in a patient with TSC. 
 
The mTOR kinase plays an important role in the translational control of gene 
expression during cell growth and proliferation, and in the overall rate of protein 
synthesis. Growth factors primarily activate mTOR and downstream pathway 
members via the phosphoinositide 3-kinase/Akt pathway. Akt phosphorylates tuberin 
to inhibit its function as a GTPase activating protein for Rheb, which in turn activates 
mTOR 5. Then mTOR directly phosphorylates p70S6 protein kinase (S6K) and 
eukaryotic initiation factor 4E binding protein 1 (4E-BP1) which promotes cell growth 
through an increase in translation. In TSC, genetic mutations inhibit the association of 
tuberin and hamartin leading to an aberrant upregulation of the mTOR signaling 
pathway 9,10.  
 
TSC2 mutations like in this patient are associated with more pronounced disease in 
general and more pronounced development of facial angiofibroma in particular than 
TSC1 mutations 11,12. Nine months into treatment with rapamycin, facial 
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angiofibromas in this patient regressed significantly. The facial angiofibromas were 
slowly progressive prior to rapamycin treatment and were not affected by the 
treatment with tacrolimus and mycophenolate mofetil. An angiofibroma consists of 
vascular and interstitial cells that express angiogenic factors like vascular endothelial 
growth factor (VEGF). VEGF, a downstream effector of the hypoxia-inducible factor 
(HIF), is one of the most important stimulatory factors for angiogenesis. The 
connection between the mTOR and HIF/VEGF signaling is incompletely understood 
although VEGF levels are higher in cells lacking TSC1/TSC2 and high VEGF levels 
are reduced by rapamycin in mouse models of TSC 13,14 The inhibition of mTOR 
decreases the production of VEGF through inhibition of HIF expression and by 
directly repressing VEGF driven endothelial cell proliferation and morphogenesis 15,16. 
Recently the beneficial effect of rapamycin on TSC lesions in the brain, lung and 
kidney of humans were reported 17-20. Our case provides evidence for the concept 
that the mTOR signalling pathway is involved in the formation of facial angiofibromas. 
The ability of rapamycin to inhibit the activity of mTOR like the tuberin/hamartin 
complex may explain the remarkable efficacy of rapamycin in our patient. 
 
The quality of life of the patient has significantly improved on the one hand due to 
elimination of the risk for new life-threatening bleeding, and on the other hand and 
most noticeably to the patient, the greatly improved cosmetic appearance. Systemic 
and topical formulations of rapamycin may thus be of value in particular for facial 
angiofibroma which in patients’ eyes is one of the most disturbing features in 
tuberous sclerosis.  
 
Conflict of interest: none 
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Figure legends 
 
Figure 1 
Improvement of facial angiofibroma lesions in a 21 year old TSC patient during 
rapamycin therapy. Panels at left, labeled 0 before the administration of rapamycin. 
Pronounced improvement was observed at 3, 6 and 9 months after the start of 
systemic rapamycin therapy (panels from left to right, labeled 3, 6 and 9).
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